Literature DB >> 9420861

Androgens and therapeutic aspects of antiandrogens in women.

E Diamanti-Kandarakis1, G Tolis, A J Duleba.   

Abstract

OBJECTIVES: We reviewed the mechanisms of androgen actions and the established and experimental uses of antiandrogens in women.
METHODS: Relevant studies were identified through a computerized bibliographic search (MEDLINE) and through manual review of bibliographies in relevant publications.
RESULTS: Androgens exert major effects on the functions of gonads, sex organs, and various "nonreproductive" organs and systems, including muscles, liver, skin, nervous system, and the immune system. Most, but not all, of the actions of androgens may be explained by their binding with specific androgen receptors. Antiandrogens prevent androgens from expressing their activity at target cells. They act primarily by binding to androgen receptors and thus preventing activation of receptors by androgens. Steroidal antiandrogens may also exert a wide range of other hormonal and antihormonal effects by interacting with receptors for progesterone, glucocorticoids, and mineralocorticoids. Furthermore, some antiandrogens may decrease the production of androgens by acting at the hypothalamic-pituitary unit and modifying the release of LH, or by directly inhibiting individual enzymes involved in steroidogenesis. Antiandrogens are widely used in the treatment of women with various hyperandrogenic conditions, including polycystic ovary syndrome, idiopathic hirsutism, acne, seborrhea, and hair loss.
CONCLUSIONS: Antiandrogens provide a logical and clinically effective pharmacotherapy of hyperandrogenic disorders. However, both steroidal and nonsteroidal antiandrogens may cause significant side effects, largely because of their interactions not only with androgen receptors, but also with other receptors and various enzymatic activities. Difficulties in designing the optimal antiandrogen largely result from the complexities of androgen metabolism and action in various tissues.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 9420861     DOI: 10.1016/1071-5576(95)00002-v

Source DB:  PubMed          Journal:  J Soc Gynecol Investig        ISSN: 1071-5576


  6 in total

1.  Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile.

Authors:  E Zulian; P Sartorato; S Benedini; G Baro; D Armanini; F Mantero; C Scaroni
Journal:  J Endocrinol Invest       Date:  2005-01       Impact factor: 4.256

Review 2.  How actual is the treatment with antiandrogen alone in patients with polycystic ovary syndrome?

Authors:  E Diamanti-Kandarakis
Journal:  J Endocrinol Invest       Date:  1998-10       Impact factor: 4.256

Review 3.  Progestogens with antiandrogenic properties.

Authors:  Daniel Raudrant; Thomas Rabe
Journal:  Drugs       Date:  2003       Impact factor: 9.546

4.  Transcriptome Sequencing in the Preoptic Region of Rat Dams Reveals a Role of Androgen Receptor in the Control of Maternal Behavior.

Authors:  András H Lékó; Rashmi Kumari; Fanni Dóra; Dávid Keller; Edina B Udvari; Vivien Csikós; Éva Renner; Arpád Dobolyi
Journal:  Int J Mol Sci       Date:  2021-02-03       Impact factor: 5.923

5.  Efficacy of Spironolactone in Adult Acne in Polycystic Ovary Syndrome Patients an Original Research.

Authors:  Neha Rani; Prashant Kumar; Anup Kumar Mishra; Bala Yadu Vamsi Sankuratri; Sanjana Sethi; Kalyani Gelada; Heena Tiwari
Journal:  J Pharm Bioallied Sci       Date:  2021-11-10

6.  Effects of Androgen Excess-Related Metabolic Disturbances on Granulosa Cell Function and Follicular Development.

Authors:  Baoying Liao; Xinyu Qi; Chuyu Yun; Jie Qiao; Yanli Pang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-14       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.